Generated by AI
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases. The company’s current programs target inherited disorders driven by nucleotide repeat expansion mutations, with a portfolio that includes treatments in development for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease. Its approach centers on designing therapeutic candidates that act on the underlying genetic cause of disease rather than only addressing symptoms. Design Therapeutics serves the biotechnology and drug-development market through its proprietary platform, which supports research, preclinical work, and clinical development of novel medicines for patients with high unmet medical needs. The company is headquartered in Carlsbad, California.
Website6005 Hidden Valley Road
Carlsbad, CA, 92011
United States
The latest articles about DSGN.
Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.
Design Therapeutics initiated at Hold: DT-216P2 shows early FA RESTORE-FA gains; watch Q4 '26/Q1 '27 catalysts and cash runway. Click for more on DSGN stock.
Wells Fargo rates Design Therapeutics overweight, citing DT-216P2’s RESTORE-FA data and best-in-disease potential vs Skyclarys. Read more here.
Summary of May 18's posts. Generated by AI.
Summary of Apr 30's posts. Generated by AI.
No summary yet.
No summary yet.
Investors talking about DSGN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.